X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4925) 4925
Publication (417) 417
Newsletter (203) 203
Book Review (60) 60
Magazine Article (8) 8
Book Chapter (6) 6
Conference Proceeding (4) 4
Book / eBook (3) 3
Dissertation (2) 2
Newspaper Article (2) 2
Trade Publication Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
docetaxel (4476) 4476
humans (3428) 3428
index medicus (2586) 2586
oncology (2259) 2259
pharmacology & pharmacy (2088) 2088
female (1737) 1737
male (1675) 1675
chemotherapy (1654) 1654
cancer (1449) 1449
middle aged (1156) 1156
paclitaxel (1091) 1091
aged (1081) 1081
animals (1062) 1062
taxoids - administration & dosage (889) 889
cell line, tumor (883) 883
adult (814) 814
antineoplastic combined chemotherapy protocols - therapeutic use (811) 811
taxoids - pharmacology (794) 794
antineoplastic agents - pharmacology (778) 778
treatment outcome (644) 644
breast cancer (636) 636
breast neoplasms - drug therapy (636) 636
prostate cancer (628) 628
mice (626) 626
research (625) 625
antineoplastic agents - therapeutic use (621) 621
pharmacology/toxicology (613) 613
care and treatment (608) 608
medicine & public health (576) 576
therapy (572) 572
cisplatin (508) 508
apoptosis (507) 507
lung neoplasms - drug therapy (501) 501
drug therapy (487) 487
analysis (478) 478
antineoplastic agents (475) 475
taxoids - therapeutic use (475) 475
antineoplastic agents - administration & dosage (446) 446
antineoplastic combined chemotherapy protocols - adverse effects (446) 446
nanoparticles (446) 446
metastasis (445) 445
prostatic neoplasms - drug therapy (432) 432
antimitotic agents (428) 428
pharmacokinetics (424) 424
apoptosis - drug effects (416) 416
carcinoma, non-small-cell lung - drug therapy (411) 411
trial (410) 410
tumors (388) 388
doxorubicin (377) 377
dose-response relationship, drug (376) 376
taxoids (370) 370
expression (369) 369
breast neoplasms - pathology (362) 362
cancer research (356) 356
in-vitro (343) 343
aged, 80 and over (341) 341
drug delivery systems (341) 341
drugs (341) 341
paclitaxel - analogs & derivatives (334) 334
cell proliferation - drug effects (330) 330
breast-cancer (329) 329
taxoids - pharmacokinetics (326) 326
drug resistance, neoplasm (324) 324
cancer therapies (323) 323
taxoids - adverse effects (323) 323
drug administration schedule (322) 322
carcinoma (320) 320
disease-free survival (319) 319
dosage and administration (314) 314
neoplasms - drug therapy (313) 313
prostatic neoplasms - pathology (313) 313
clinical trials (312) 312
paclitaxel - pharmacology (309) 309
pharmacology (309) 309
combination (308) 308
survival (308) 308
neoplasm metastasis (307) 307
phase-ii trial (303) 303
health aspects (302) 302
cell survival - drug effects (296) 296
lung neoplasms - pathology (289) 289
lung cancer (286) 286
antineoplastic agents - pharmacokinetics (285) 285
paclitaxel - administration & dosage (285) 285
xenograft model antitumor assays (282) 282
antineoplastic agents - adverse effects (281) 281
cell lung-cancer (280) 280
phase-ii (276) 276
antineoplastic combined chemotherapy protocols - administration & dosage (266) 266
mice, nude (263) 263
antineoplastic agents, phytogenic - pharmacology (262) 262
toxicity (261) 261
taxoids - chemistry (257) 257
lung cancer, non-small cell (255) 255
complications and side effects (249) 249
gemcitabine (244) 244
mitoxantrone (242) 242
survival analysis (240) 240
oncology, experimental (236) 236
neoplasm staging (235) 235
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5093) 5093
Japanese (20) 20
French (15) 15
Italian (6) 6
Chinese (5) 5
Spanish (5) 5
Dutch (2) 2
Korean (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 01/2016, Volume 30, pp. 144 - 154
imaging and biodistribution analysis of nude mice bearing HepG2 tumors after tail vein injection of free IR-780, or IR-780 loaded TPGS-PLA/NPs or... 
Liver targeting | Dopamine polymerization | Surface modification | Cancer nanotechnology | Galactosylated nanoparticles | Taxoids - pharmacology | Nanoparticles - chemistry | Humans | Vitamin E - analogs & derivatives | Polyethylene Glycols - chemistry | Lactic Acid - pharmacokinetics | Liver Neoplasms, Experimental - metabolism | Carcinoma, Hepatocellular - drug therapy | Polyesters | Indoles - pharmacology | Vitamin E - chemistry | Lactic Acid - pharmacology | Liver Neoplasms, Experimental - pathology | Polyethylene Glycols - pharmacology | Taxoids - chemistry | Lactic Acid - chemistry | Vitamin E - pharmacokinetics | Polyethylene Glycols - pharmacokinetics | Hep G2 Cells | Taxoids - pharmacokinetics | Xenograft Model Antitumor Assays | Animals | Liver Neoplasms, Experimental - drug therapy | Mice, Nude | Carcinoma, Hepatocellular - pathology | Polymers - pharmacokinetics | Polymers - pharmacology | Indoles - pharmacokinetics | Polymers - chemistry | Mice | Drug Delivery Systems - methods | Indoles - chemistry | Carcinoma, Hepatocellular - metabolism | Vitamin E - pharmacology | Drugs | Liver cancer | Drug delivery systems | Docetaxel | Vehicles | Nanoparticles | Polyethylene glycol | Tocopherols | Polymerization | Polyols | Nanotechnology | Surgical implants | Biomedical materials | In vivo testing | Liver | In vivo tests | Palladium | Tumors | Cancer
Journal Article
Oncotarget, ISSN 1949-2553, 2014, Volume 5, Issue 22, pp. 11399 - 11412
Journal Article
Nature, ISSN 0028-0836, 01/2010, Volume 463, Issue 7277, pp. 103 - 107
MCL1 is essential for the survival of stem and progenitor cells of multiple lineages(1,2), and is unique among pro-survival BCL2 family members in that it is... 
MULTIPLE-MYELOMA | BREAST-CANCER | APOPTOSIS | IN-VITRO | ACTIVATION | UBIQUITIN LIGASE | PATHWAY | MULTIDISCIPLINARY SCIENCES | PROTEINS | BCL-2 FAMILY | EXPRESSION | Neoplasms - metabolism | Prognosis | Taxoids - pharmacology | Apoptosis - drug effects | Humans | Gene Expression Regulation, Neoplastic | Half-Life | Neoplasms - diagnosis | Gene Knockdown Techniques | Proto-Oncogene Proteins c-bcl-2 - metabolism | Ubiquitination | Ultraviolet Rays | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | RNA Interference | Ubiquitin Thiolesterase - deficiency | Protein Binding - radiation effects | Ubiquitin Thiolesterase - metabolism | Female | Lysine - metabolism | Protein Stability | Polyubiquitin - metabolism | Cell Line | Cell Survival | Docetaxel | Etoposide - pharmacology | Mice, SCID | Sulfonamides - pharmacology | Ubiquitin Thiolesterase - genetics | Piperazines - pharmacology | Xenograft Model Antitumor Assays | Phosphorylation - radiation effects | Animals | Myeloid Cell Leukemia Sequence 1 Protein | Cell Line, Tumor | Mice | DNA Damage | Neoplasms - pathology | Proto-Oncogene Proteins c-bcl-2 - genetics | Care and treatment | Multiple myeloma | Physiological aspects | Genetic aspects | Research | Ubiquitin-proteasome system | Health aspects | Oncogenes | Cancer | Proteins | Lymphomas | Mass spectrometry | Apoptosis
Journal Article
European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 3, pp. 319 - 327
Journal Article
Cancer Research, ISSN 0008-5472, 11/2009, Volume 69, Issue 21, pp. 8386 - 8394
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2014, Volume 73, Issue 4, pp. 729 - 736
Journal Article
Cancer Letters, ISSN 0304-3835, 2011, Volume 309, Issue 2, pp. 228 - 235
Highlights ► Pemetrexed-resistant non-small cell lung cancer cell lines have not been reported. ► They remained sensitive to docetaxel, vinorelbine,... 
Hematology, Oncology and Palliative Medicine | Resistance | Thymidylate synthase | Pemetrexed | Non-small cell lung cancer | CARBOPLATIN | REDUCED FOLATE CARRIER | ANTIFOLATE | CHEMOTHERAPY | LY231514 | CISPLATIN PLUS GEMCITABINE | ONCOLOGY | RANDOMIZED PHASE-III | EXPRESSION | Cell Proliferation | Taxoids - pharmacology | Adenocarcinoma of Lung | Guanine - analogs & derivatives | Humans | Lung Neoplasms - metabolism | Immunoblotting | Adenocarcinoma - metabolism | Vinblastine - analogs & derivatives | Guanine - pharmacology | Thymidylate Synthase - biosynthesis | Adenocarcinoma - genetics | Antineoplastic Agents - pharmacology | Phosphoribosylglycinamide Formyltransferase - genetics | Camptothecin - analogs & derivatives | Lung Neoplasms - genetics | Gene Expression | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Docetaxel | Cisplatin - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Tetrahydrofolate Dehydrogenase - biosynthesis | Thymidylate Synthase - genetics | Irinotecan | Drug Resistance, Neoplasm - genetics | Glutamates - pharmacology | Cell Line, Tumor | Fluorouracil - pharmacology | Vinblastine - pharmacology | Camptothecin - pharmacology | Folic Acid Antagonists - pharmacology | Vinorelbine | Tetrahydrofolate Dehydrogenase - genetics | Lung cancer, Non-small cell | Fluorouracil | Chemotherapy | Dihydrofolate reductase | Drug therapy | Cancer therapies | Lung cancer | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2012, Volume 106, Issue 5, pp. 858 - 866
BACKGROUND: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical... 
temozolomide | scheduling | apoptosis | Selumetinib | barasertib | docetaxel | PROTEIN | PHOSPHORYLATION | MAP KINASE | G/M TRANSITION | MULTIPLE-MYELOMA CELLS | SPINDLE-CHECKPOINT | IN-VITRO | ONCOLOGY | MELANOMA-CELLS | KINASE KINASE INHIBITION | PHASE-I | Taxoids - pharmacology | Apoptosis - drug effects | Dacarbazine - therapeutic use | Humans | Organophosphates - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasms, Experimental - pathology | Taxoids - therapeutic use | Benzimidazoles - administration & dosage | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Benzimidazoles - therapeutic use | Organophosphates - administration & dosage | MAP Kinase Kinase 1 - antagonists & inhibitors | Dacarbazine - administration & dosage | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Organophosphates - pharmacology | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | MAP Kinase Signaling System - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Mice, Nude | Quinazolines - therapeutic use | Cell Line, Tumor | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Neoplasms, Experimental - drug therapy | Translational Therapeutics
Journal Article
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 11, pp. 2710 - 2718
Abstract The biodegradable polymer medium chain length polyhydroxyalkanoate (mclPHA), produced by Pseudomonas putida CA-3, was depolymerised and the... 
Advanced Basic Science | Dentistry | Cancer biology | Monomer | Polyhydroxyalkanoate | Antimicrobial peptides | (R)-3-hydroxydecanoic acid | Apoptosis | MATERIALS SCIENCE, BIOMATERIALS | SOLID-PHASE SYNTHESIS | ENGINEERING, BIOMEDICAL | MEMBRANE | MITOCHONDRIA | ANTIBACTERIAL | CANCER | HOST-DEFENSE PEPTIDES | LEUKEMIA-CELLS | CECROPIN-A | HYBRID PEPTIDES | Deoxycytidine - chemistry | Taxoids - pharmacology | Apoptosis - drug effects | Biocompatible Materials - chemistry | Humans | Deoxycytidine - pharmacology | Polyhydroxyalkanoates - pharmacology | Cisplatin - chemistry | Decanoic Acids - chemistry | Inhibitory Concentration 50 | Anticarcinogenic Agents - pharmacology | Biodegradation, Environmental | Taxoids - chemistry | Cell Survival | Decanoic Acids - pharmacology | Antimicrobial Cationic Peptides - pharmacology | Polyhydroxyalkanoates - chemistry | Biocompatible Materials - pharmacology | Cisplatin - pharmacology | Blotting, Western | Drug Synergism | HT29 Cells | Microscopy, Confocal | Fluorescent Antibody Technique | Cell Line, Tumor | Cell Proliferation - drug effects | HeLa Cells | Deoxycytidine - analogs & derivatives | Care and treatment | Biological products | Hydroxides | Peptides | Medical societies | Oncology, Experimental | Docetaxel | Mitochondrial DNA | Research | Cells | Nuclear nonproliferation | Saturated fatty acids | Cancer
Journal Article